<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>IMBRUVICA- ibrutinib capsule </strong><br>Pharmacyclics, Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. <br><br>IMBRUVICA<span class="Sup">®</span> (ibrutinib) capsules, for oral use <br><br>Initial U.S. Approval: 2013</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="top" width="90%">
<col align="right" valign="top" width="10%">
<tbody class="Headless">
<tr>
<td align="left">Indications and Usage (<a href="#S1.4">1.4</a>)</td>
<td align="right">01/15</td>
</tr>
<tr>
<td align="left">Dosage and Administration (<a href="#S2.2">2.2</a>, <a href="#S2.3">2.3</a>, <a href="#S2.5">2.5</a>) </td>
<td align="right">01/15</td>
</tr>
<tr>
<td align="left">Warnings and Precautions (<a href="#S5.1">5.1</a>, <a href="#S5.6">5.6</a>)</td>
<td align="right">01/15</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with: </p>
<ul>
<li>Mantle cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (MCL) who have received at least one prior therapy (<a href="#S1.1">1.1</a>). <br>Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.</li>
<li><span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic lymphocytic leukemia</span> (CLL) who have received at least one prior therapy (<a href="#S1.2">1.2</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic lymphocytic leukemia</span> with 17p deletion (<a href="#S1.3">1.3</a>).</li>
<li>Waldenström's macroglobulinemia (WM) (<a href="#S1.4">1.4</a>).</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">MCL: 560 mg taken orally once daily (four 140 mg capsules once daily) (<a href="#S2.2">2.2</a>).  </p>
<p class="Highlighta">CLL and WM: 420 mg taken orally once daily (three 140 mg capsules once daily) (<a href="#S2.2">2.2</a>). </p>
<p class="Highlighta">Capsules should be taken orally with a glass of water. Do not open, break, or chew the capsules (<a href="#S2.1">2.1</a>). </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsule: 140 mg (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>: Monitor for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#S5.1">5.1</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: Monitor patients for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and evaluate promptly (<a href="#S5.2">5.2</a>). </li>
<li><span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span>: Check complete blood counts monthly (<a href="#S5.3">5.3</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span>: Monitor patients for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (<a href="#S5.4">5.4</a>). </li>
<li>Second Primary Malignancies: Other malignancies have occurred in patients, including skin cancers, and other carcinomas (<a href="#S5.5">5.5</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span> (TLS): Monitor patients at risk for TLS (e.g. high tumor burden) (<a href="#S5.6">5.6</a>).</li>
<li>Embryo-Fetal Toxicity: Can cause fetal harm. Advise women of the potential risk to a fetus and to avoid pregnancy while taking the drug (<a href="#S5.7">5.7</a>). </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (≥25%) in patients with B-cell malignancies (MCL, CLL, WM) were <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.  (<a href="#section-6">6</a>)</p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pharmacyclics at 1-877-877-3536 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span>  (<a href="#section-6">6</a>)</p>
</div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">CYP3A Inhibitors: Avoid co-administration with strong and moderate CYP3A inhibitors. If a moderate CYP3A inhibitor must be used, reduce IMBRUVICA dose (<a href="#S2.4">2.4</a>, <a href="#S7.1">7.1</a>). </p>
<p class="Highlighta">CYP3A Inducers: Avoid co-administration with strong CYP3A inducers (<a href="#S7.2">7.2</a>). </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Avoid use of IMBRUVICA in patients with moderate or severe baseline <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In patients with mild impairment, reduce IMBRUVICA dose (<a href="#S8.7">8.7</a>).   </p></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div><div></div></div>
</div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Mantle Cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2	<span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span> </a></h2>
<h2><a href="#section-1.3" class="toc">1.3 	<span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span> with 17p deletion</a></h2>
<h2><a href="#section-1.4" class="toc">1.4	Waldenström's Macroglobulinemia</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Dosing Guidelines</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dosage</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Dose Modifications for Adverse Reactions</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Dose Modifications for Use with CYP3A Inhibitors</a></h2>
<h2><a href="#section-2.5" class="toc">2.5	Dose Modifications for Use in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.6" class="toc">2.6	Missed Dose</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Second Primary Malignancies</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Embryo-Fetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6. 2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	CYP3A Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	CYP3A Inducers</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8	Females and Males of Reproductive Potential</a></h2>
<h2><a href="#section-8.8" class="toc">8.9	Plasmapheresis</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1	Mantle Cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></a></h2>
<h2><a href="#section-12.2" class="toc">14.2 	<span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span></a></h2>
<h2><a href="#section-12.3" class="toc">14.3	Waldenström's Macroglobulinemia</a></h2>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Mantle Cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></h2>
<p class="First">IMBRUVICA is indicated for the treatment of patients with mantle cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (MCL) who have received at least one prior therapy. </p>
<p>Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	<span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span> </h2>
<p class="First">IMBRUVICA is indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> (CLL) who have received at least one prior therapy <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 	<span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span> with 17p deletion</h2>
<p class="First">IMBRUVICA is indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> (CLL) with 17p deletion <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.4"></a><a name="section-1.4"></a><p></p>
<h2>1.4	Waldenström's Macroglobulinemia</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">IMBRUVICA is indicated for the treatment of patients with Waldenström's macroglobulinemia (WM) <span class="Italics">[see <a href="#S14.3">Clinical Studies (14.3)</a>]</span>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Dosing Guidelines</h2>
<p class="First">Administer IMBRUVICA orally once daily at approximately the same time each day. Swallow the capsules whole with water. Do not open, break, or chew the capsules.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dosage</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Bold">Mantle Cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">The recommended dose of IMBRUVICA for MCL is 560 mg (four 140 mg capsules) orally once daily.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span> and Waldenström's Macroglobulinemia</span></p>
<p>The recommended dose of IMBRUVICA for CLL and WM is 420 mg (three 140 mg capsules) orally once daily.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Dose Modifications for Adverse Reactions</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Interrupt IMBRUVICA therapy for any Grade 3 or greater non-hematological, Grade 3 or greater <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or Grade 4 hematological toxicities. Once the symptoms of the toxicity have resolved to Grade 1 or baseline (recovery), IMBRUVICA therapy may be reinitiated at the starting dose. If the toxicity reoccurs, reduce dose by one capsule (140 mg per day). A second reduction of dose by 140 mg may be considered as needed. If these toxicities persist or recur following two dose reductions, discontinue IMBRUVICA.</span></p>
<p>Recommended dose modifications are described below: </p>
<table width="90%">
<col align="left" valign="bottom" width="30%">
<col align="left" valign="top" width="35%">
<col align="left" valign="top" width="35%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Toxicity Occurrence</th>
<th class="Rrule" align="left" valign="bottom">MCL Dose Modification After Recovery<br>Starting Dose = 560 mg</th>
<th class="Rrule" align="left" valign="bottom">CLL and WM Dose Modification After Recovery<br>Starting Dose = 420 mg</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">First</td>
<td class="Rrule" align="left">Restart at 560 mg daily</td>
<td class="Rrule" align="left">Restart at 420 mg daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Second</td>
<td class="Rrule" align="left">Restart at 420 mg daily</td>
<td class="Rrule" align="left">Restart at 280 mg daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Third</td>
<td class="Rrule" align="left">Restart at 280 mg daily</td>
<td class="Rrule" align="left">Restart at 140 mg daily</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Fourth</td>
<td class="Rrule" align="left">Discontinue IMBRUVICA</td>
<td class="Rrule" align="left">Discontinue IMBRUVICA</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Dose Modifications for Use with CYP3A Inhibitors</h2>
<p class="First">Avoid co-administration with strong or moderate CYP3A inhibitors and consider alternative agents with less CYP3A inhibition.</p>
<p>Concomitant use of strong CYP3A inhibitors which would be taken chronically (e.g., ritonavir, indinavir, nelfinavir, saquinavir, boceprevir, telaprevir, nefazodone) is not recommended. For short-term use (treatment for 7 days or less) of strong CYP3A inhibitors (e.g., antifungals and antibiotics) consider interrupting IMBRUVICA therapy until the CYP3A inhibitor is no longer needed <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>]</span>.</p>
<p>Reduce IMBRUVICA dose to 140 mg if a moderate CYP3A inhibitor must be used (e.g., fluconazole, darunavir, erythromycin, diltiazem, atazanavir, aprepitant, amprenavir, fosamprevir, crizotinib, imatinib, verapamil, and ciprofloxacin) <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>].</span></p>
<p>Patients taking concomitant strong or moderate CYP3A inhibitors should be monitored more closely for signs of IMBRUVICA toxicity. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5	Dose Modifications for Use in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">For patients with mild liver impairment (Child-Pugh class A), the recommended dose is 140 mg daily (one capsule).  Avoid the use of IMBRUVICA in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh classes B and C) <span class="Italics">[see <a href="#S8.7">Use in Specific Populations (8.7)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6	Missed Dose</h2>
<p class="First">If a dose of IMBRUVICA is not taken at the scheduled time, it can be taken as soon as possible on the same day with a return to the normal schedule the following day. Extra capsules of IMBRUVICA should not be taken to make up for the missed dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">140 mg capsules</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events have occurred in patients treated with IMBRUVICA. Grade 3 or higher <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events (<span class="product-label-link" type="condition" conceptid="4318408" conceptname="Subdural hematoma">subdural hematoma</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and <span class="product-label-link" type="condition" conceptid="4002836" conceptname="Postoperative hemorrhage">post procedural hemorrhage</span>) have occurred in up to 6% of patients. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events of any grade, including <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, occurred in approximately half of patients treated with IMBRUVICA. </span></p>
<p>The mechanism for the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events is not well understood. </p>
<p>IMBRUVICA may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> in patients receiving antiplatelet or anticoagulant therapies.</p>
<p>Consider the benefit-risk of withholding IMBRUVICA for at least 3 to 7 days pre and post-surgery depending upon the type of surgery and the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Fatal and non-fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> have occurred with IMBRUVICA therapy. Grade 3 or greater <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> occurred in 14% to 26% of patients. <span class="Italics">[See <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. Cases of <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML) have occurred in patients treated with IMBRUVICA. Monitor patients for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and evaluate promptly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span></h2>
<p class="First">Treatment-emergent Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (range, 19 to 29%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (range, 5 to 17%), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (range, 0 to 9%) occurred in patients treated with IMBRUVICA.</p>
<p>Monitor complete blood counts monthly. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span> and <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> (range, 6 to 9%) have occurred in patients treated with IMBRUVICA, particularly in patients with cardiac risk factors, acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and a previous history of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>. Periodically monitor patients clinically for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>. Patients who develop arrhythmic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>) or new onset <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> should have an ECG performed. If <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> persists, consider the risks and benefits of IMBRUVICA treatment and dose modification <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Second Primary Malignancies</h2>
<p class="First">Other malignancies (range, 5 to 14%) including non-skin carcinomas (range, 1 to 3%) have occurred in patients treated with IMBRUVICA. The most frequent second primary malignancy was non-<span class="product-label-link" type="condition" conceptid="4049499" conceptname="Malignant melanoma">melanoma skin</span> cancer (range, 4 to 11 %).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span> has been reported with IMBRUVICA therapy. Monitor patients closely and take appropriate precautions in patients at risk for <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span> (e.g. high tumor burden). </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Embryo-Fetal Toxicity</h2>
<p class="First">Based on findings in animals, IMBRUVICA can cause fetal harm when administered to a pregnant woman. Ibrutinib caused malformations in rats at exposures 14 times those reported in patients with MCL and 20 times those reported in patients with CLL or WM, receiving the ibrutinib dose of 560 mg per day and 420 mg per day, respectively. Reduced fetal weights were observed at lower exposures. Advise women to avoid becoming pregnant while taking IMBRUVICA. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li>Second Primary Malignancies <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span> <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>
</li>
</ul>
<p>Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Mantle Cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></span></p>
<p>The data described below reflect exposure to IMBRUVICA in a clinical trial that included 111 patients with previously treated MCL treated with 560 mg daily with a median treatment duration of 8.3 months.</p>
<p>The most commonly occurring adverse reactions (≥ 20%) were <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> (see <a href="#table1">Tables 1</a> and <a href="#table2">2</a>).</p>
<p>The most common Grade 3 or 4 non-hematological adverse reactions (≥ 5%) were <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span>.</p>
<p>Fatal and serious cases of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> have occurred with IMBRUVICA therapy. Increases in creatinine 1.5 to 3 times the upper limit of normal occurred in 9% of patients.</p>
<p>Adverse reactions from the MCL trial (N=111) using single agent IMBRUVICA 560 mg daily occurring at a rate of ≥ 10% are presented in Table 1. </p>
<a name="table1"></a><table width="90%">
<caption><span>Table 1:  Non-Hematologic Adverse Reactions in ≥ 10% of Patients with MCL (N=111)</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule" align="center" valign="top">System Organ Class</th>
<th class="Rrule" align="center" valign="top">Preferred Term</th>
<th class="Rrule" align="center" valign="top">All Grades (%)</th>
<th class="Rrule" align="center" valign="top">Grade 3 or 4 (%)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" rowspan="7" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">51</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="5" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td class="Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="center" valign="bottom">34</td>
<td class="Rrule" align="center" valign="bottom">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">Skin infections</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="4" valign="top"><span class="Bold">General disorders and administrative site conditions</span></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule Toprule" align="center">41</td>
<td class="Rrule Toprule" align="center">5</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="3" valign="top"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span></td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="3" valign="top"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="3" valign="top"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top"><span class="Bold">Metabolism and nutrition disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<a name="table2"></a><table width="90%">
<caption><span>Table 2:  Treatment-Emergent<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> Decrease of Hemoglobin, Platelets, or <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> in Patients with MCL (N=111)</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2"></th>
<th class="Botrule Rrule" align="center" colspan="2">Percent of Patients (N=111)</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">All Grades (%)</th>
<th class="Rrule" align="center">Grade 3 or 4 (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Based on laboratory measurements and adverse reactions</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Platelets Decreased</td>
<td class="Rrule" align="center">57</td>
<td class="Rrule" align="center">17</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> Decreased</td>
<td class="Rrule" align="center">47</td>
<td class="Rrule" align="center">29</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin Decreased</span></td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">9</td>
</tr>
</tbody>
</table>
<p>Ten patients (9%) discontinued treatment due to adverse reactions in the trial (N=111). The most frequent adverse reaction leading to treatment discontinuation was <span class="product-label-link" type="condition" conceptid="4318408" conceptname="Subdural hematoma">subdural hematoma</span> (1.8%). Adverse reactions leading to dose reduction occurred in 14% of patients.</p>
<p>Patients with MCL who develop <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span> greater than 400,000/mcL have developed <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait instability</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. However, some of these cases were in the setting of disease progression.</p>
<p>Forty percent of patients had elevated uric acid levels on study including 13% with values above 10 mg/dL. Adverse reaction of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> was reported for 15% of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span></span></p>
<p>The data described below reflect exposure to IMBRUVICA in an open label clinical trial (Study 1) that included 48 patients with previously treated CLL and a randomized clinical trial (Study 2) that included 391 randomized patients with previously treated CLL or SLL.</p>
<p>The most commonly occurring adverse reactions in Study 1 and Study 2 (≥ 20%) were <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>.</p>
<p>Approximately five percent of patients receiving IMBRUVICA in Study 1 and Study 2 discontinued treatment due to adverse events. These included <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4318408" conceptname="Subdural hematoma">subdural hematomas</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Adverse events leading to dose reduction occurred in approximately 6% of patients.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Study 1</span></p>
<p>Adverse reactions and laboratory abnormalities from the CLL trial (N=48) using single agent IMBRUVICA 420 mg daily occurring at a rate of ≥ 10% are presented in Tables 3 and 4. </p>
<a name="table3"></a><table width="100%">
<caption><span>Table 3:  Non-Hematologic Adverse Reactions in ≥ 10% of Patients with CLL (N=48) in Study 1</span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule" align="center" valign="bottom">System Organ Class</th>
<th class="Rrule" align="center" valign="bottom">Preferred Term</th>
<th class="Rrule" align="center" valign="bottom">All Grades (%)</th>
<th class="Rrule" align="center" valign="bottom">Grade 3 or 4 (%)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd><span class="Italics">One patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to histiocytic <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>.</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" rowspan="7" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">63</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="5" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">Skin infection</span></td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="5" valign="top"><span class="Bold">General disorders and administrative site conditions</span></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule Toprule" align="center">31</td>
<td class="Rrule Toprule" align="center">4</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="3" valign="top"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span></td>
<td class="Rrule" align="center">54</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span></td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="3" valign="top"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left">Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="3" valign="top"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="3" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolism and nutrition disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Neoplasms benign, malignant, unspecified</span></td>
<td class="Rrule" align="left">Second malignancies<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">10<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443419" conceptname="Laceration - injury">Laceration</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top"><span class="Bold">Psychiatric disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">8</td>
</tr>
</tbody>
</table>
<a name="table4"></a><table width="90%">
<caption><span>Table 4: Treatment-Emergent<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> Decrease of Hemoglobin, Platelets, or <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> in Patients with CLL (N=48) in Study 1</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2"></th>
<th class="Botrule Rrule" align="center" colspan="2">Percent of Patients (N=48)</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">All Grades (%)</th>
<th class="Rrule" align="center">Grade 3 or 4 (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Based on laboratory measurements per IWCLL criteria and adverse reactions</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Platelets Decreased</td>
<td class="Rrule" align="center">71</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> Decreased</td>
<td class="Rrule" align="center">54</td>
<td class="Rrule" align="center">27</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin Decreased</span></td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2.2"></a><p></p>
<p class="First"><span class="Bold Italics">Study 2</span></p>
<p>Adverse reactions and laboratory abnormalities described below in Tables 5 and 6 reflect exposure to IMBRUVICA with a median duration of 8.6 months and exposure to ofatumumab with a median of 5.3 months in Study 2.</p>
<a name="table5"></a><table width="100%">
<caption><span>Table 5:  Non-Hematologic Adverse Reactions ≥ 10% Reported in Study 2</span></caption>
<col align="left" valign="top" width="32%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">IMBRUVICA<br>(N=195)</th>
<th class="Botrule Rrule" align="center" colspan="2">Ofatumumab<br>(N=191)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center" valign="bottom">System Organ Class ADR Term</th>
<th class="Rrule" align="center">All Grades (%)</th>
<th class="Rrule" align="center">Grade 3 or 4 (%)</th>
<th class="Rrule" align="center">All Grades (%)</th>
<th class="Rrule" align="center">Grade 3 or 4 (%)</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top">Subjects with multiple events for a given ADR term are counted once only for each ADR term.</td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top">The system organ class and individual ADR terms are sorted in descending frequency order in the IMBRUVICA arm.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Includes multiple ADR terms</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">General disorders and administration site conditions</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span><a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span><a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span><a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal Pain</span><a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusion</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<a name="table6"></a><table width="100%">
<caption><span>Table 6: Treatment-Emergent<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> Decrease of Hemoglobin, Platelets, or <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> in Study 2</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="17%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">IMBRUVICA<br>(N=195)</th>
<th class="Rrule" align="center" colspan="2">Ofatumumab<br>(N=191)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">All Grades (%)</th>
<th class="Rrule" align="center">Grade 3 or 4 (%)</th>
<th class="Rrule" align="center">All Grades (%)</th>
<th class="Rrule" align="center">Grade 3 or 4 (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Based on laboratory measurements per IWCLL criteria</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> Decreased</td>
<td class="Rrule" align="center">51</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">57</td>
<td class="Rrule" align="center">26</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Platelets Decreased</td>
<td class="Rrule" align="center">52</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">45</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin Decreased</span></td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Underline">Waldenström's Macroglobulinemia</span></p>
<p>The data described below reflect exposure to IMBRUVICA in an open label clinical trial that included 63 patients with previously treated WM.</p>
<p>The most commonly occurring adverse reactions in the WM trial (≥ 20%) were <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.</p>
<p>Six percent of patients receiving IMBRUVICA in the WM trial discontinued treatment due to adverse events. Adverse events leading to dose reduction occurred in 11% of patients.</p>
<p>Adverse reactions and laboratory abnormalities described below in Tables 7 and 8 reflect exposure to IMBRUVICA with a median duration of 11.7 months in the WM trial.</p>
<a name="table7"></a><table width="100%">
<caption><span>Table 7:  Non-Hematologic Adverse Reactions in ≥ 10% of Patients with Waldenström's Macroglobulinemia (N=63)</span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="bottom">System Organ Class</th>
<th class="Rrule" align="center" valign="bottom">Preferred Term</th>
<th class="Rrule" align="center" valign="bottom">All Grades (%)</th>
<th class="Rrule" align="center" valign="bottom">Grade 3 or 4 (%)</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="4">The system organ class and individual ADR terms are sorted in descending frequency order.</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Includes multiple ADR terms.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal reflux disease</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="3">Skin and subcutaneous tissue disorders</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><a href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span><a href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">General disorders and administrative site conditions</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="2">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span> </td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthropathy</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" rowspan="4"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span><a href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">Skin infection</span><a href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" rowspan="2">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Neoplasms benign, malignant, and unspecified (including <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> and <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span>)</td>
<td class="Rrule" align="left">Skin cancer<a href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<a name="table8"></a><table width="90%">
<caption><span>Table 8:  Treatment-Emergent<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a> Decrease of Hemoglobin, Platelets, or <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> in Patients with WM (N=63)</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2"></th>
<th class="Botrule Rrule" align="center" colspan="2">Percent of Patients (N=63)</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">All Grades (%)</th>
<th class="Rrule" align="center">Grade 3 or 4 (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Based on laboratory measurements.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Platelets Decreased</td>
<td class="Rrule" align="center">43</td>
<td class="Rrule" align="center">13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> Decreased</td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">19</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin Decreased</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">8</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6. 2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of IMBRUVICA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> (fatal), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> have been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Ibrutinib is primarily metabolized by cytochrome P450 enzyme 3A.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	CYP3A Inhibitors</h2>
<p class="First">In healthy volunteers, co-administration of ketoconazole, a strong CYP3A inhibitor, increased C<span class="Sub">max</span> and AUC of ibrutinib by 29- and 24-fold, respectively. The highest ibrutinib dose evaluated in clinical trials was 12.5 mg/kg (actual doses of 840 – 1400 mg) given for 28 days with single dose AUC values of 1445 ± 869 ng ∙ hr/mL which is approximately 50% greater than steady state exposures seen at the highest indicated dose (560 mg).</p>
<p>Avoid concomitant administration of IMBRUVICA with strong or moderate inhibitors of CYP3A. For strong CYP3A inhibitors used short-term (e.g., antifungals and antibiotics for 7 days or less, e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin) consider interrupting IMBRUVICA therapy during the duration of inhibitor use. Avoid strong CYP3A inhibitors that are needed chronically. If a moderate CYP3A inhibitor must be used, reduce the IMBRUVICA dose. Patients taking concomitant strong or moderate CYP3A4 inhibitors should be monitored more closely for signs of IMBRUVICA toxicity <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a>]</span>. </p>
<p>Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain moderate inhibitors of CYP3A <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	CYP3A Inducers</h2>
<p class="First">Administration of IMBRUVICA with rifampin, a strong CYP3A inducer, decreased ibrutinib C<span class="Sub">max</span> and AUC by approximately 13- and 10-fold, respectively.</p>
<p>Avoid concomitant use of strong CYP3A inducers (e.g., carbamazepine, rifampin, phenytoin and St. John's Wort). Consider alternative agents with less CYP3A induction <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category D <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>Based on findings in animals, IMBRUVICA can cause fetal harm when administered to a pregnant woman. If IMBRUVICA is used during pregnancy or if the patient becomes pregnant while taking IMBRUVICA, the patient should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>Ibrutinib was administered orally to pregnant rats during the period of organogenesis at oral doses of 10, 40 and 80 mg/kg/day. Ibrutinib at a dose of 80 mg/kg/day was associated with visceral malformations (heart and major vessels) and increased post-implantation loss. The dose of 80 mg/kg/day in animals is approximately 14 times the exposure (AUC) in patients with MCL and 20 times the exposure in patients with CLL or WM administered the dose of 560 mg daily and 420 mg daily, respectively. Ibrutinib at doses of 40 mg/kg/day or greater was associated with decreased fetal weights. The dose of 40 mg/kg/day in animals is approximately 6 times the exposure (AUC) in patients with MCL administered the dose of 560 mg daily.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether ibrutinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from IMBRUVICA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of IMBRUVICA in pediatric patients has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 111 patients treated for MCL, 63% were 65 years of age or older. No overall differences in effectiveness were observed between these patients and younger patients. Cardiac adverse events (<span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>) and gastrointestinal events (<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>) occurred more frequently among elderly patients.  </p>
<p>Of the 391 patients randomized in Study 2, 61% were ≥ 65 years of age. No overall differences in effectiveness were observed between age groups. Grade 3 or higher adverse events occurred more frequently among elderly patients treated with IMBRUVICA (61% of patients age ≥ 65 versus 51% of younger patients) <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<p>Of the 63 patients treated for WM, 59% were 65 years of age or older. No overall differences in effectiveness were observed between these patients and younger patients. Cardiac adverse events (<span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>), and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>) occurred more frequently among elderly patients.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Less than 1% of ibrutinib is excreted renally. Ibrutinib exposure is not altered in patients with Creatinine clearance (CLcr) &gt; 25 mL/min. There are no data in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr &lt; 25 mL/min) or patients on dialysis <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Ibrutinib is metabolized in the liver. In a <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> study, data showed an increase in ibrutinib exposure.  Following single dose administration, the AUC of ibrutinib increased 2.7-, 8.2- and 9.8-fold in subjects with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to subjects with normal liver function. The safety of IMBRUVICA has not been evaluated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
<p>Monitor patients for signs of IMBRUVICA toxicity and follow dose modification guidance as needed. It is not recommended to administer IMBRUVICA to patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh classes B and C) <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8	Females and Males of Reproductive Potential</h2>
<p class="First">Advise women to avoid becoming pregnant while taking IMBRUVICA because IMBRUVICA can cause fetal harm <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.9"></a><a name="section-8.8"></a><p></p>
<h2>8.9	Plasmapheresis</h2>
<p class="First">Management of hyperviscosity in patients with WM may include plasmapheresis before and during treatment with IMBRUVICA. Modifications to IMBRUVICA dosing are not required.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). It is a white to off-white solid with the empirical formula C25H24N6O2 and a molecular weight 440.50. Ibrutinib is freely soluble in dimethyl sulfoxide, soluble in methanol and practically insoluble in water.</p>
<p>The chemical name for ibrutinib is 1-[(3<span class="Italics">R</span>)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and has the following structure:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44&amp;name=imbruvica-01.jpg"></p>
<p>IMBRUVICA (ibrutinib) capsules for oral administration are supplied as white opaque capsules that contain 140 mg ibrutinib as the active ingredient. Each capsule also contains the following inactive ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. The capsule shell contains gelatin, titanium dioxide and black ink. Each white opaque capsule is marked with "ibr 140 mg" in black ink.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK's role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span>. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> in vitro.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In patients with recurrent B-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> &gt; 90% occupancy of the BTK active site in peripheral blood mononuclear cells was observed up to 24 hours after ibrutinib doses of ≥ 2.5 mg/kg/day (≥ 175 mg/day for average weight of 70 kg).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption </span></p>
<p>Ibrutinib is absorbed after oral administration with a median T<span class="Sub">max</span> of 1 to 2 hours. Ibrutinib exposure increases with doses up to 840 mg. The steady-state AUC (mean ± standard deviation) observed in patients at 560 mg is 953 ± 705 ng∙h/mL and in patients at 420 mg is 680 ± 517 ng∙h/mL. Administration with food increased ibrutinib C<span class="Sub">max</span> and AUC by approximately 2 to 4- and 2-fold, respectively, compared with administration of ibrutinib after overnight fasting.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.2"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<p>Reversible binding of ibrutinib to human plasma protein in vitro was 97.3% with no concentration <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in the range of 50 to 1000 ng/mL. The volume of distribution at steady state (V<span class="Sub">d,ss</span>) was 683 L, and the apparent volume of distribution at steady state (V<span class="Sub">d,ss</span>/F) was approximately 10000 L.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism</span></p>
<p>Metabolism is the main route of elimination for ibrutinib. It is metabolized to several metabolites primarily by cytochrome P450, CYP3A, and to a minor extent by CYP2D6. The active metabolite, PCI-45227, is a dihydrodiol metabolite with inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib. The range of the mean metabolite to parent ratio for PCI-45227 at steady-state is 1 to 2.8.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.4"></a><p></p>
<p class="First"><span class="Bold">Elimination</span></p>
<p>Intravenous clearance was 62 and 76 L/h in fasted and fed conditions, respectively. In line with the high first-pass effect, the apparent oral clearance is approximately 2000 and 1000 L/h in fasted and fed conditions, respectively. The half-life of ibrutinib is 4 to 6 hours.</p>
<p>Ibrutinib, mainly in the form of metabolites, is eliminated primarily via feces. After a single oral administration of radiolabeled [<span class="Sup">14</span>C]-ibrutinib in healthy subjects, approximately 90% of radioactivity was excreted within 168 hours, with the majority (80%) excreted in the feces and less than 10% accounted for in urine. Unchanged ibrutinib accounted for approximately 1% of the radiolabeled excretion product in feces and none in urine, with the remainder of the dose being metabolites.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.5"></a><p></p>
<p class="First"><span class="Bold">Age</span></p>
<p>Age (37 to 84 years) does not alter ibrutinib systemic clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.6"></a><p></p>
<p class="First"><span class="Bold">Gender</span></p>
<p>Gender does not alter ibrutinib systemic clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.7"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Ibrutinib is not significantly cleared renally; urinary excretion of metabolites is &lt; 10% of the dose. Creatinine clearance &gt; 25 mL/min had no influence on the exposure to IMBRUVICA. There are no data in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr &lt; 25 mL/min) or in patients on dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.8"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Ibrutinib is metabolized in the liver. In a <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> trial, a single dose of 140 mg of IMBRUVICA was administered in non-cancer subjects. Ibrutinib AUC increased 2.7-, 8.2- and 9.8-fold, respectively, in subjects with mild (n=6), moderate (n=10) and severe (n=8) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> relative to subjects with normal liver function.  Ibrutinib C<span class="Sub">max</span> increased 5.2-, 8.8- and 7.0-fold, respectively, in subjects with mild, moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> relative  to subjects with normal liver function <span class="Italics">[see <a href="#S8.7">Use in Specific Populations (8.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.9"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.9.1"></a><p></p>
<p class="First"><span class="Italics">Coadministration of Ibrutinib with CYP3A Inhibitors</span></p>
<p>In a sequential design trial of 18 healthy, fasted volunteers, a single dose of 120 mg of IMBRUVICA was administered alone on Day 1 and a single dose of 40 mg of IMBRUVICA was administered on Day 7 in combination with 400 mg of ketoconazole (given daily on Days 4 – 9). Ketoconazole increased ibrutinib dose-normalized C<span class="Sub">max</span> and AUC 29-fold and 24-fold, respectively. Simulations using fasted conditions indicate that moderate CYP3A inhibitors diltiazem and erythromycin may increase AUC of ibrutinib by 5- to 8-fold.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.9.2"></a><p></p>
<p class="First"><span class="Italics">Coadministration of Ibrutinib with CYP3A Inducers</span></p>
<p>PK data from a dedicated drug interaction trial showed that rifampin (a strong CYP3A inducer) decreases ibrutinib C<span class="Sub">max</span> and AUC by more than 13- and 10-fold. Simulations using PBPK suggested that a moderate CYP3A inducer (efavirenz) may decrease the AUC of ibrutinib by up to 3-fold.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.9.3"></a><p></p>
<p class="First"><span class="Italics">Coadministration of Ibrutinib with CYP Substrates</span></p>
<p>In vitro studies indicated that ibrutinib (I/Ki &lt; 0.07 using mean C<span class="Sub">max</span> at 560 mg) and PCI-45227 (I/Ki &lt; 0.03) are unlikely to be inhibitors of any major CYPs at clinical doses. Both ibrutinib and the PCI-45227 are weak inducers of CYP450 isoenzymes in vitro.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.9.4"></a><p></p>
<p class="First"><span class="Italics">Coadministration of Ibrutinib with Substrates of Transporters</span></p>
<p>In vitro studies indicated that ibrutinib is not a substrate of p-glycoprotein (P-gp). Systemic ibrutinib is unlikely to be an inhibitor of P-gp at clinical doses ([I]<span class="Sub">1</span>/Ki &lt; 0.1). However, it may have an effect on P-gp substrates in the GI tract due to higher local concentrations after an oral dose. Co-administration of oral narrow therapeutic index P-gp substrates (e.g., digoxin) with IMBRUVICA may increase their blood concentration.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies have not been conducted with ibrutinib.</p>
<p>Ibrutinib was not mutagenic in a bacterial mutagenicity (Ames) assay, was not clastogenic in a chromosome aberration assay in mammalian (CHO) cells, nor was it clastogenic in an in vivo bone marrow micronucleus assay in mice at doses up to 2000 mg/kg.</p>
<p>Fertility studies with ibrutinib have not been conducted in animals. In the general toxicology studies conducted in rats and dogs, orally administered ibrutinib did not result in adverse effects on reproductive organs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-12.1"></a><p></p>
<h2>14.1	Mantle Cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></h2>
<p class="First">The safety and efficacy of IMBRUVICA in patients with MCL who have received at least one prior therapy were evaluated in an open-label, multi-center, single-arm trial of 111 previously treated patients. The median age was 68 years (range, 40 to 84 years), 77% were male, and 92% were Caucasian. At baseline, 89% of patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 42 months, and median number of prior treatments was 3 (range, 1 to 5 treatments), including 11% with prior stem cell transplant. At baseline, 39% of subjects had at least one tumor ≥ 5 cm, 49% had bone marrow involvement, and 54% had extranodal involvement at screening.</p>
<p>IMBRUVICA was administered orally at 560 mg once daily until disease progression or unacceptable toxicity. Tumor response was assessed according to the revised International Working Group (IWG) for non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (NHL) criteria. The primary endpoint in this study was investigator-assessed overall response rate (ORR). Responses to IMBRUVICA are shown in Table 9.</p>
<a name="table9"></a><table width="80%">
<caption><span>Table 9:  Overall Response Rate (ORR) and Duration of Response (DOR) Based on Investigator Assessment in Patients with MCL</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Total (N=111)</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="2">CI = confidence interval; CR = complete response; PR = partial response; NR = not reached</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">ORR (%)</td>
<td class="Rrule" align="center">65.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  95% CI (%)</td>
<td class="Rrule" align="center">(56.2, 74.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  CR (%)</td>
<td class="Rrule" align="center">17.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  PR (%)</td>
<td class="Rrule" align="center">48.6</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Median DOR months (95% CI) </td>
<td class="Rrule" align="center">17.5 (15.8, NR)</td>
</tr>
</tbody>
</table>
<p>An Independent Review Committee (IRC) performed independent reading and interpretation of imaging scans. The IRC review demonstrated an ORR of 69%.</p>
<p>The median time to response was 1.9 months.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">Lymphocytosis</span></span></p>
<p>Upon initiation of IMBRUVICA, a temporary increase in lymphocyte counts (i.e., ≥ 50% increase from baseline and above absolute lymphocyte count of 5,000/mcL) occurred in 33% of patients in the MCL study. The onset of isolated <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span> occurs during the first few weeks of IMBRUVICA therapy and resolves by a median of 8 weeks.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-12.2"></a><p></p>
<h2>14.2 	<span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span></h2>
<p class="First">The safety and efficacy of IMBRUVICA in patients with CLL who have received at least one prior therapy were demonstrated in one uncontrolled trial and one randomized, controlled trial.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Study 1</span></p>
<p>An open-label, multi-center trial was conducted in 48 previously treated CLL patients. The median age was 67 years (range, 37 to 82 years), 71% were male, and 94% were Caucasian. All patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 80 months and the median number of prior treatments was 4 (range, 1 to 12 treatments). At baseline, 46% of subjects had at least one tumor ≥ 5 cm.</p>
<p>IMBRUVICA was administered orally at 420 mg once daily until disease progression or unacceptable toxicity. The ORR and DOR were assessed using a modified version of the International Workshop on CLL Criteria by an Independent Review Committee. The ORR was 58.3% (95% CI: 43.2%, 72.4%), all partial responses. None of the patients achieved a complete response. The DOR ranged from 5.6 to 24.2+ months. The median DOR was not reached.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.2"></a><p></p>
<p class="First"><span class="Bold Italics">Study 2</span></p>
<p>A randomized, multicenter, open-label Phase 3 study of IMBRUVICA versus ofatumumab was conducted in patients with previously treated CLL or SLL. Patients (n=391) were randomized 1:1 to receive either IMBRUVICA 420 mg daily until disease progression, or unacceptable toxicity or ofatumumab at an initial dose of 300 mg, followed one week later by a dose of 2000 mg weekly for 7 doses and then every 4 weeks for 4 additional doses. Fifty seven patients randomized to ofatumumab crossed over following progression to receive IMBRUVICA. The median age was 67 years (range, 30 to 88 years), 68% were male, and 90% were Caucasian. All patients had a baseline ECOG performance status of 0 or 1. The trial enrolled 373 patients with CLL and 18 patients with SLL.  The median time since diagnosis was 91 months and the median number of prior treatments was 2 (range, 1 to 13 treatments). At baseline, 58% of patients had at least one tumor ≥ 5 cm. Thirty-two percent of patients had 17p deletion. </p>
<p>Progression free survival (PFS) as assessed by independent review committee (IRC) according to IWCLL criteria indicated a 78% statistically significant reduction in the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or progression. Analysis of overall survival (OS) demonstrated a 57% statistically significant reduction in the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> for patients in the IMBRUVICA arm. Efficacy results for Study 2 are shown in Table 10 and the Kaplan-Meier curves for PFS and OS are shown in Figures 1 and 2, respectively.</p>
<a name="table10"></a><table width="90%">
<caption><span>Table 10:  Efficacy Results in Study 2</span></caption>
<col align="left" valign="bottom" width="34%">
<col align="center" valign="bottom" width="33%">
<col align="center" valign="bottom" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Endpoint</th>
<th class="Rrule" align="center">IMBRUVICA<br>N=195</th>
<th class="Rrule" align="center">Ofatumumab<br>N=196</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">HR = hazard ratio </td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Median OS not reached for either arm</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>IRC evaluated. All partial responses achieved; none of the patients achieved a complete response.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Progression Free Survival</span></td>
<td class="Rrule" align="center" colspan="2"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Number of events (%)</td>
<td class="Rrule" align="center">35 (17.9)</td>
<td class="Rrule" align="center">111 (56.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Median (95% CI), months</td>
<td class="Rrule" align="center">Not reached</td>
<td class="Rrule" align="center">8.1 (7.2, 8.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  HR (95% CI)</td>
<td class="Rrule" align="center" colspan="2">0.22 (0.15, 0.32)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Overall Survival<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></span></td>
<td class="Rrule" align="center" colspan="2"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (%)</td>
<td class="Rrule" align="center">16 (8.2)</td>
<td class="Rrule" align="center">33 (16.8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  HR (95% CI)</td>
<td class="Rrule" align="center" colspan="2">0.43 (0.24, 0.79)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Overall Response Rate<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">42.6%</td>
<td class="Rrule" align="center">4.1%</td>
</tr>
</tbody>
</table>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center"><span class="Bold">Figure 1:  Kaplan-Meier Curve of Progression-Free Survival (ITT Population) in Study 2</span></td></tr>
<tr><td align="left"><p class="First"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44&amp;name=imbruvica-02.jpg"></p></td></tr>
</tbody>
</table>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center"><span class="Bold">Figure 2:  Kaplan-Meier Curve of Overall Survival (ITT Population) in Study 2</span></td></tr>
<tr><td align="left"><p class="First"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44&amp;name=imbruvica-03.jpg"></p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3"></a><p></p>
<p class="First"><span class="Bold Italics">CLL with 17p deletion (del 17p CLL)</span></p>
<p>Study 2 included 127 patients with del 17p CLL.  The median age was 67 years (range, 30 to 84 years), 62% were male, and 88% were Caucasian. All patients had a baseline ECOG performance status of 0 or 1. PFS and ORR were assessed by IRC.  Efficacy results for del 17p CLL are shown in Table 11.</p>
<a name="table11"></a><table width="90%">
<caption><span>Table 11:  Efficacy Results in Patients with del 17p CLL </span></caption>
<col align="left" valign="bottom" width="34%">
<col align="center" valign="bottom" width="33%">
<col align="center" valign="bottom" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Endpoint</th>
<th class="Rrule" align="center">IMBRUVICA<br>N=63</th>
<th class="Rrule" align="center">Ofatumumab<br>N=64</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">HR = hazard ratio </td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>IRC evaluated. All partial responses achieved; none of the patients achieved a complete response.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Progression Free Survival</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Number of events (%)</td>
<td class="Rrule" align="center">16 (25.4)</td>
<td class="Rrule" align="center">38 (59.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Median (95% CI), months</td>
<td class="Rrule" align="center">Not reached</td>
<td class="Rrule" align="center">5.8 (5.3, 7.9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  HR (95% CI)</td>
<td class="Rrule" align="center" colspan="2">0.25  (0.14, 0.45)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Overall Response Rate<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a>
</td>
<td class="Rrule" align="center">47.6%</td>
<td class="Rrule" align="center">4.7%</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">Lymphocytosis</span></span></p>
<p>Upon initiation of IMBRUVICA, an increase in lymphocyte counts (i.e., ≥ 50% increase from baseline and above absolute lymphocyte count of 5,000/mcL) occurred in 77% of patients in the CLL study. The onset of isolated <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span> occurs during the first month of IMBRUVICA therapy and resolves by a median of 23 weeks (range 1 – 104+ weeks).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-12.3"></a><p></p>
<h2>14.3	Waldenström's Macroglobulinemia</h2>
<p class="First">The safety and efficacy of IMBRUVICA in WM were evaluated in an open-label, multi-center, single-arm trial of 63 previously treated patients. The median age was 63 years (range, 44 to 86 years), 76% were male, and 95% were Caucasian. All patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 74 months, and the median number of prior treatments was 2 (range, 1 to 11 treatments). At baseline, the median serum IgM value was 3.5 g/dL (range, 0.7 to 8.4 g/dL).</p>
<p>IMBRUVICA was administered orally at 420 mg once daily until disease progression or unacceptable toxicity. The responses were assessed by investigators and an Independent Review Committee (IRC) using criteria adopted from the International Workshop of Waldenström's Macroglobulinemia. Responses, defined as partial response or better, per IRC are shown in Table 12.</p>
<a name="table12"></a><table width="90%">
<caption><span>Table 12:  Response Rate and Duration of Response Based on IRC Assessment in Patients with WM</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="bottom" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" valign="top">Total (N=63)</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="2">CI = confidence interval; NR = not reached</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Response rate (CR+VGPR+PR), (%)</td>
<td class="Rrule" align="center">61.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  95% CI (%)</td>
<td class="Rrule" align="center">(48.8, 73.9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Complete Response (CR)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Very Good Partial Response (VGPR), (%)</td>
<td class="Rrule" align="center">11.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Partial Response (PR), (%)</td>
<td class="Rrule" align="center">50.8</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Median duration of response, months (range) </td>
<td class="Rrule" align="center">NR (2.8+, 18.8+)</td>
</tr>
</tbody>
</table>
<p>The median time to response was 1.2 months (range: 0.7–13.4 months). </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">The white opaque 140 mg capsules marked with "ibr 140 mg" in black ink are available in white HDPE bottles with a child-resistant closure:</p>
<ul>
<li>90 capsules per bottle:  NDC 57962-140-09</li>
<li>120 capsules per bottle:  NDC 57962-140-12</li>
</ul>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.1"></a><p></p>
<p class="First">Store bottles at room temperature 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F to 86°F). Retain in original package until dispensing.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (<a href="#PI">Patient Information</a>).</p>
<ul>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>:</span><br>Inform patients of the possibility of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and to report any signs or symptoms (<span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">blood in stools</span> or urine, prolonged or uncontrolled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>). Inform the patient that IMBRUVICA may need to be interrupted for medical or dental procedures <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</span><br>Inform patients of the possibility of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and to report any signs or symptoms (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>) suggestive of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></span>: <br>Counsel patients to report any signs of <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, and <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</li>
<li>
<span class="Italics">Second primary malignancies:</span><br>Inform patients that other malignancies have occurred in patients who have been treated with IMBRUVICA, including skin cancers and other carcinomas <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span>:</span><br>Inform patients of the potential risk of <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span> and report any signs and symptoms associated with this event to their healthcare provider for evaluation [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a>].</span>
</li>
<li>
<span class="Italics">Embryo-fetal toxicity:</span><br>Advise women of the potential hazard to a fetus and to avoid becoming pregnant <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>.</li>
<li>Inform patients to take IMBRUVICA orally once daily according to their physician's instructions and that the capsules should be swallowed whole with a glass of water without being opened, broken, or chewed at approximately the same time each day <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a>]</span>.</li>
<li>Advise patients that in the event of a missed daily dose of IMBRUVICA, it should be taken as soon as possible on the same day with a return to the normal schedule the following day. Patients should not take extra capsules to make up the missed dose <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>]</span>.</li>
<li>Advise patients of the common side effects associated with IMBRUVICA <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>]</span>. Direct the patient to a complete list of adverse drug reactions in PATIENT INFORMATION.</li>
<li>Advise patients to inform their health care providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span>.</li>
<li>Advise patients that they may experience <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and should contact their doctor if their <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> persists.  Advise patients to maintain adequate hydration.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">Active ingredient made in China.</p>
<p>Distributed and Marketed by:<br>Pharmacyclics, Inc.<br>Sunnyvale, CA USA 94085<br>and<br>Marketed by:<br>Janssen Biotech, Inc.<br>Horsham, PA USA 19044</p>
<p>Patent <span class="Italics">http://www.imbruvica.com</span><br>IMBRUVICA<span class="Sup">®</span> is a registered trademark owned by Pharmacyclics, Inc.</p>
<p>© Pharmacyclics, Inc. 2015<br>© Janssen Biotech, Inc. 2015</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="PI"></a><a name="section-16"></a><p></p>
<table width="100%">
<col align="left" valign="top" width="100%">
<tfoot><tr class="First Last"><td align="left" colspan="1">This Patient Information has been approved by the U.S. Food and Drug Administration.<br>Revised: 01/2015</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center">
<span class="Bold">Patient Information<br>IMBRUVICA (im-BRU-vih-kuh)</span><br>(ibrutinib) capsules</td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">What is IMBRUVICA?</span></td></tr>
<tr><td class="Lrule Rrule" align="left">IMBRUVICA is a prescription medicine used to treat people with:</td></tr>
<tr><td class="Lrule Rrule" align="left"><ul class="Disc">
<li>Mantle cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (MCL) who have received at least one prior treatment</li>
<li><span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic lymphocytic leukemia</span> (CLL) who have received at least one prior treatment </li>
<li><span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic lymphocytic leukemia</span> (CLL) with 17p deletion</li>
<li>Waldenstrom's macroglobulinemia (WM)</li>
</ul></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left">It is not known if IMBRUVICA is safe and effective in children.</td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">What should I tell my healthcare provider before taking IMBRUVICA?</span></td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">Before you take IMBRUVICA, tell your healthcare provider about all of your medical conditions, including if you:</span></td></tr>
<tr><td class="Lrule Rrule" align="left"><ul class="Disc">
<li>have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA for any planned medical, surgical, or dental procedure.</li>
<li>have <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li>have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></li>
<li>have liver problems </li>
<li>are pregnant or plan to become pregnant. IMBRUVICA can harm your unborn baby. You should not become pregnant while taking IMBRUVICA.</li>
<li>are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will take IMBRUVICA or breastfeed. You should not do both.</li>
</ul></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left">
<span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA with certain other medicines may affect how IMBRUVICA works and can cause side effects.</td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">How should I take IMBRUVICA?</span></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left"><ul class="Disc">
<li>Take IMBRUVICA exactly as your healthcare provider tells you to take it.</li>
<li>Take IMBRUVICA 1 time a day. </li>
<li>Swallow IMBRUVICA capsules whole with a glass of water. Do not open, break, or chew IMBRUVICA capsules.</li>
<li>Take IMBRUVICA at about the same time each day.</li>
<li>If you miss a dose of IMBRUVICA take it as soon as you remember on the same day. Take your next dose of IMBRUVICA at your regular time on the next day. Do not take 2 doses of IMBRUVICA on the same day to make up for a missed dose.</li>
</ul></td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">What should I avoid while taking IMBRUVICA?</span></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left"><ul class="Disc"><li>You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) while you are taking IMBRUVICA. These products may increase the amount of IMBRUVICA in your blood.</li></ul></td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">What are the possible side effects of IMBRUVICA?</span></td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">IMBRUVICA may cause serious side effects, including:</span></td></tr>
<tr><td class="Lrule Rrule" align="left"><ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> problems</span> can happen during treatment with IMBRUVICA that can be serious and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Tell your healthcare provider if you have any signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including: blood in your stools or <span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">black stools</span> (looks like tar), pink or brown urine, unexpected <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> up blood or blood clots, increased <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, feel dizzy or weak, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, change in your speech, or a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> that lasts a long time. Your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may increase if you are also taking a blood thinner medicine.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span> can happen during treatment with IMBRUVICA. These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be serious and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Tell your healthcare provider right away if you have <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or other signs or symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> while taking IMBRUVICA.</li>
<li>
<span class="Bold">Decrease in blood cell counts.</span> Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA, but can also be severe. Your healthcare provider should do monthly blood tests to check your blood counts.</li>
<li>
<span class="Bold">Heart rhythm problems (<span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>).</span> Heart rhythm problems have happened in people treated with IMBRUVICA, especially in people who have an increased risk for heart disease, have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or who have had heart rhythm problems in the past. Tell your healthcare provider if you get any symptoms of heart rhythm problems, such as feeling as if your heart is beating fast and irregular, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, or you <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>.</li>
<li>
<span class="Bold">Second primary cancers.</span> New cancers have happened in people who have been treated with IMBRUVICA, including cancers of the skin or other organs.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span> (TLS).</span> TLS is caused by the fast breakdown of cancer cells. TLS can cause <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and the need for dialysis treatment, abnormal heart rhythm, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, and sometimes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your healthcare provider may do blood tests to check you for TLS.</li>
<li>
<span class="Bold">Kidney problems.</span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Kidney failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have happened in people with MCL receiving IMBRUVICA treatment.</li>
</ul></td></tr>
<tr><td class="Lrule Rrule" align="left">
<span class="Bold">The most common side effects of IMBRUVICA include:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, muscle and <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common side effect in people who take IMBRUVICA. Drink plenty of fluids during treatment with IMBRUVICA to help reduce your risk of losing too much fluid (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>) due to <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Tell your healthcare provider if you have <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not go away.</span></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left">These are not all the possible side effects of IMBRUVICA. <br>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">How should I store IMBRUVICA?</span></td></tr>
<tr><td class="Lrule Rrule" align="left"><ul class="Disc">
<li>Store IMBRUVICA at room temperature between 68°F to 77°F (20°C to 25°C).</li>
<li>Keep IMBRUVICA in the original container with the lid tightly closed.</li>
</ul></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left"><span class="Bold">Keep IMBRUVICA and all medicines out of the reach of children.</span></td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">General information about the safe and effective use of IMBRUVICA</span></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left">Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA for a condition for which it was not prescribed. Do not give IMBRUVICA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA that is written for health professionals.</td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">What are the ingredients in IMBRUVICA?</span></td></tr>
<tr><td class="Lrule Rrule" align="left">
<span class="Bold">Active ingredient:</span> ibrutinib</td></tr>
<tr><td class="Lrule Rrule" align="left">
<span class="Bold">Inactive ingredients:</span> croscarmellose sodium, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. The capsule shell contains gelatin, titanium dioxide and black ink.</td></tr>
<tr class="Last"><td class="Lrule Rrule" align="left">Distributed and Marketed by: Pharmacyclics, Inc. Sunnyvale, CA USA 94085 and <br>Marketed by: Janssen Biotech, Inc. Horsham, PA USA 19044   For more information call 1-877-877-3536.<br>© Pharmacyclics, Inc. 2015<br>© Janssen Biotech, Inc. 2015</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 90 Capsule Bottle Carton</h1>
<p class="First">NDC 57962-140-09</p>
<p><span class="Bold">Imbruvica<span class="Sup">®</span><br>(ibrutinib) capsules</span></p>
<p><span class="Bold">140 mg</span></p>
<p>Each capsule contains: ibrutinib 140 mg<br>Swallow capsules whole with water</p>
<p><span class="Bold">90 Capsules</span></p>
<p>Rx Only</p>
<p><span class="Bold Italics">pharmacyclics</span><span class="Bold"><span class="Sup">®</span></span></p>
<p>Janssen</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 90 Capsule Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44&amp;name=imbruvica-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IMBRUVICA 		
					</strong><br><span class="contentTableReg">ibrutinib capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57962-140</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Ibrutinib</strong> (Ibrutinib) </td>
<td class="formItem">Ibrutinib</td>
<td class="formItem">140 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ibr140mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57962-140-09</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:57962-140-12</td>
<td class="formItem">120  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205552</td>
<td class="formItem">11/07/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pharmacyclics, Inc
							(791179526)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacyclics, Inc</td>
<td class="formItem"></td>
<td class="formItem">791179526</td>
<td class="formItem">ANALYSIS(57962-140)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lonza Guangzhou Nansha Ltd.</td>
<td class="formItem"></td>
<td class="formItem">545328150</td>
<td class="formItem">API MANUFACTURE(57962-140)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Micron Technologies</td>
<td class="formItem"></td>
<td class="formItem">226428217</td>
<td class="formItem">PARTICLE SIZE REDUCTION(57962-140)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent CTS Inc</td>
<td class="formItem"></td>
<td class="formItem">962674474</td>
<td class="formItem">MANUFACTURE(57962-140), ANALYSIS(57962-140)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">AndersonBrecon Inc.</td>
<td class="formItem"></td>
<td class="formItem">098908572</td>
<td class="formItem">PACK(57962-140)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cc0396b7-6b5b-4b3c-8d7e-803a8dad0bd3</div>
<div>Set id: 0dfd0279-ff17-4ea9-89be-9803c71bab44</div>
<div>Version: 6</div>
<div>Effective Time: 20150213</div>
</div>
</div> <div class="DistributorName">Pharmacyclics, Inc</div></p>
</body></html>
